Chromocell Therapeutics Corp. (AMEX: CHRO) established initial surge of 35.78% at $1.02, before settling in for the price of $0.75 at the close. Taking a more long-term approach, CHRO posted a 52-week range of $0.58-$6.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of -33.33% over the last 5 years. This publicly-traded company’s shares outstanding now amounts to $5.88 million, simultaneously with a float of $1.06 million. The organization now has a market capitalization sitting at $5.89 million. At the time of writing, stock’s 50-day Moving Average stood at $0.9258.
Chromocell Therapeutics Corp. (CHRO) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Chromocell Therapeutics Corp. industry. Chromocell Therapeutics Corp.’s current insider ownership accounts for 81.69%, in contrast to 9.34% institutional ownership. According to the most recent insider trade that took place on Sep 12 ’24, this organization’s Director bought 10,400 shares at the rate of 0.94, making the entire transaction reach 9,825 in total value, affecting insider ownership by 91,565. Preceding that transaction, on Sep 13 ’24, Company’s CEO, Pres., CFO, Treas & Secty bought 3,500 for 0.97, making the whole transaction’s value amount to 3,395. This particular insider is now the holder of 547,710 in total.
Chromocell Therapeutics Corp. (CHRO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
Chromocell Therapeutics Corp. (AMEX: CHRO) Trading Performance Indicators
Let’s observe the current performance indicators for Chromocell Therapeutics Corp. (CHRO). It’s Quick Ratio in the last reported quarter now stands at 0.93. The Stock has managed to achieve an average true range (ATR) of 0.14.
In the same vein, CHRO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.68, a figure that is expected to reach -0.23 in the next quarter.
Technical Analysis of Chromocell Therapeutics Corp. (CHRO)
Now, what If we examine the latest scores posted by [Chromocell Therapeutics Corp., CHRO]. During the last 5-days, its volume was better the volume of 33610.0 it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 49.50% While, its Average True Range was 0.1500.
Raw Stochastic average of Chromocell Therapeutics Corp. (CHRO) in the period of the previous 100 days is set at 20.00%, which indicates a major fall in contrast to 80.43% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 146.09% that was higher than 138.16% volatility it exhibited in the past 100-days period.
